Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease
No Thumbnail
Authors
Lucafo, MariannaStanković, Biljana
Kotur, Nikola
Di Silvestre, Alessia
Martelossi, Stefano
Ventura, Alessandro
Zukić, Branka
Pavlović, Sonja
Decorti, Giuliana
Article (Published version)
Metadata
Show full item recordAbstract
Background: Pharmacotranscriptomics aims to reach more accurate drug dosing based on interindividual transcriptome variations. Here, we provide an overview of RNA biomarkers that could predict the response to glucocorticoids (GCs), considered the standard for treatment of inflammatory bowel diseases (IBD), both in adult and pediatric patients. Although new biological agents are very effective in IBD treatment, GCs are still widely used for induction of remission in patients with moderate to severe disease. It is important to identify patients that are poor responders to GCs therapy, because suboptimal response is frequent and associated with various side effects. A number of genetic variants related to GC mechanism of action has been studied. However, the majority of reported associations are not consistent. In this regard, pharmacogenomic research is now exploring the world of RNAs. An appropriate regulation of the transcriptome, which mainly comprises mRNAs and non-coding RNAs that c...ontrol gene expression, has a strong impact in the modulation of GC activity. Aim: The aim of this review is to present the current knowledge of the role of the transcriptome in modulating GC response in pediatric IBD. Results: We will discuss the available literature, concerning the development of pharmacotranscriptomic biomarkers, focusing particularly on non-coding RNAs, and present the results in this field that elucidate a concrete benefit of translating the knowledge gained in the "omics" studies into clinical practice.
Keywords:
pharmacotrascriptomics / microRNA / long non-coding RNA / inflammatory bowel disease. biomarker / GlucocorticoidsSource:
Current Medicinal Chemistry, 2018, 25, 24, 2855-2871Publisher:
- Bentham Science Publ Ltd, Sharjah
Funding / projects:
- Rare Diseases:Molecular Pathophysiology, Diagnostic and Therapeutic Modalities and Social, Ethical and Legal Aspects (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
DOI: 10.2174/0929867324666170920145337
ISSN: 0929-8673
PubMed: 28933291
WoS: 000440790600008
Scopus: 2-s2.0-85045195657
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Lucafo, Marianna AU - Stanković, Biljana AU - Kotur, Nikola AU - Di Silvestre, Alessia AU - Martelossi, Stefano AU - Ventura, Alessandro AU - Zukić, Branka AU - Pavlović, Sonja AU - Decorti, Giuliana PY - 2018 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1120 AB - Background: Pharmacotranscriptomics aims to reach more accurate drug dosing based on interindividual transcriptome variations. Here, we provide an overview of RNA biomarkers that could predict the response to glucocorticoids (GCs), considered the standard for treatment of inflammatory bowel diseases (IBD), both in adult and pediatric patients. Although new biological agents are very effective in IBD treatment, GCs are still widely used for induction of remission in patients with moderate to severe disease. It is important to identify patients that are poor responders to GCs therapy, because suboptimal response is frequent and associated with various side effects. A number of genetic variants related to GC mechanism of action has been studied. However, the majority of reported associations are not consistent. In this regard, pharmacogenomic research is now exploring the world of RNAs. An appropriate regulation of the transcriptome, which mainly comprises mRNAs and non-coding RNAs that control gene expression, has a strong impact in the modulation of GC activity. Aim: The aim of this review is to present the current knowledge of the role of the transcriptome in modulating GC response in pediatric IBD. Results: We will discuss the available literature, concerning the development of pharmacotranscriptomic biomarkers, focusing particularly on non-coding RNAs, and present the results in this field that elucidate a concrete benefit of translating the knowledge gained in the "omics" studies into clinical practice. PB - Bentham Science Publ Ltd, Sharjah T2 - Current Medicinal Chemistry T1 - Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease EP - 2871 IS - 24 SP - 2855 VL - 25 DO - 10.2174/0929867324666170920145337 ER -
@article{ author = "Lucafo, Marianna and Stanković, Biljana and Kotur, Nikola and Di Silvestre, Alessia and Martelossi, Stefano and Ventura, Alessandro and Zukić, Branka and Pavlović, Sonja and Decorti, Giuliana", year = "2018", abstract = "Background: Pharmacotranscriptomics aims to reach more accurate drug dosing based on interindividual transcriptome variations. Here, we provide an overview of RNA biomarkers that could predict the response to glucocorticoids (GCs), considered the standard for treatment of inflammatory bowel diseases (IBD), both in adult and pediatric patients. Although new biological agents are very effective in IBD treatment, GCs are still widely used for induction of remission in patients with moderate to severe disease. It is important to identify patients that are poor responders to GCs therapy, because suboptimal response is frequent and associated with various side effects. A number of genetic variants related to GC mechanism of action has been studied. However, the majority of reported associations are not consistent. In this regard, pharmacogenomic research is now exploring the world of RNAs. An appropriate regulation of the transcriptome, which mainly comprises mRNAs and non-coding RNAs that control gene expression, has a strong impact in the modulation of GC activity. Aim: The aim of this review is to present the current knowledge of the role of the transcriptome in modulating GC response in pediatric IBD. Results: We will discuss the available literature, concerning the development of pharmacotranscriptomic biomarkers, focusing particularly on non-coding RNAs, and present the results in this field that elucidate a concrete benefit of translating the knowledge gained in the "omics" studies into clinical practice.", publisher = "Bentham Science Publ Ltd, Sharjah", journal = "Current Medicinal Chemistry", title = "Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease", pages = "2871-2855", number = "24", volume = "25", doi = "10.2174/0929867324666170920145337" }
Lucafo, M., Stanković, B., Kotur, N., Di Silvestre, A., Martelossi, S., Ventura, A., Zukić, B., Pavlović, S.,& Decorti, G.. (2018). Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease. in Current Medicinal Chemistry Bentham Science Publ Ltd, Sharjah., 25(24), 2855-2871. https://doi.org/10.2174/0929867324666170920145337
Lucafo M, Stanković B, Kotur N, Di Silvestre A, Martelossi S, Ventura A, Zukić B, Pavlović S, Decorti G. Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease. in Current Medicinal Chemistry. 2018;25(24):2855-2871. doi:10.2174/0929867324666170920145337 .
Lucafo, Marianna, Stanković, Biljana, Kotur, Nikola, Di Silvestre, Alessia, Martelossi, Stefano, Ventura, Alessandro, Zukić, Branka, Pavlović, Sonja, Decorti, Giuliana, "Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease" in Current Medicinal Chemistry, 25, no. 24 (2018):2855-2871, https://doi.org/10.2174/0929867324666170920145337 . .